Cipro HC is developed by Farmoquimica S.A..

What development phase is Cipro HC in?

Cipro HC is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Cipro HC

Farmoquimica S.A. · FDA-approved active Small molecule Quality 2/100

Cipro HC, marketed by Farmoquimica S.A., is an established product in its therapeutic category. The key composition patent is set to expire in 2028, providing a period of market exclusivity that supports current revenue streams. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Cipro HC
Sponsor	Farmoquimica S.A.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cipro HC CI brief — competitive landscape report
Cipro HC updates RSS · CI watch RSS
Farmoquimica S.A. portfolio CI